Osteoporosis in older people

被引:2
作者
Inderjeeth, Charles A. [1 ,2 ,3 ]
Inderjeeth, Keenan A. [4 ,5 ]
机构
[1] Univ Western Australia, Sch Med & Pharmacol, Crawley, Australia
[2] Sir Charles Gairdner & Osborne Pk Hosp Grp, Nedlands, WA, Australia
[3] Arthrit & Osteoporosis WA, Perth, WA, Australia
[4] Dent Esthet, Subiaco, WA, Australia
[5] Captain Stirling Compounding Pharm, Nedlands, WA, Australia
关键词
aged; bone density conservation agents; fracture; geriatrics; osteoporosis; DENOSUMAB DISCONTINUATION; FRACTURE PROBABILITY; VERTEBRAL FRACTURES; BISPHOSPHONATES; WOMEN; OSTEONECROSIS; MANAGEMENT; REDUCTION; EFFICACY; POSITION;
D O I
10.1002/jppr.1743
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis prevalence is increasing with an ageing demographic. Osteoporosis and fracture risk increases with age due to falls, frailty and comorbidities. Although there is a paucity of data in older populations over 70 years of age, the available evidence suggests that they benefit from multifactorial intervention including management of comorbidities, polypharmacy, fall risk, vitamin D and calcium optimisation and pharmacological interventions. Although the reduction in risk from these strategies is similar to younger people, the absolute risk reduction is greater in older people due to higher absolute fracture risk. Older people, however, present unique challenges. Although the imperative to treat is greater, there are multiple competing factors: frailty, comorbidities, drug interactions, greater likelihood of medical interventions for periodontal and dental disease, gastrointestinal issues limiting oral therapies and cognitive issues affecting adherence. Pharmacists are well placed as a key member of the multidisciplinary team to optimise management of this cohort.
引用
收藏
页码:265 / 274
页数:10
相关论文
共 49 条
[31]  
Nguyen TV, 2004, MED J AUSTRALIA, V180, pS18
[32]   Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment [J].
Nicolatou-Galitis, Ourania ;
Schiodt, Morten ;
Mendes, Rui Amaral ;
Ripamonti, Carla ;
Hope, Sally ;
Drudge-Coates, Lawrence ;
Niepel, Daniela ;
Van den Wyngaert, Tim .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2019, 127 (02) :117-135
[33]   Burden of high fracture probability worldwide: secular increases 2010-2040 [J].
Oden, A. ;
McCloskey, E. V. ;
Kanis, J. A. ;
Harvey, N. C. ;
Johansson, H. .
OSTEOPOROSIS INTERNATIONAL, 2015, 26 (09) :2243-2248
[34]   Cohort Profile: Geelong Osteoporosis Study [J].
Pasco, Julie A. ;
Nicholson, Geoff C. ;
Kotowicz, Mark A. .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2012, 41 (06) :1565-1575
[35]  
Raymond W, 2018, INT J CLIN RHEUMATOL, V13, DOI [10.4172/1758-4272.1000156, DOI 10.4172/1758-4272.1000156]
[36]   Bone Loss After Denosumab: Only Partial Protection with Zoledronate [J].
Reid, Ian R. ;
Horne, Anne M. ;
Mihov, Borislav ;
Gamble, Gregory D. .
CALCIFIED TISSUE INTERNATIONAL, 2017, 101 (04) :371-374
[37]   EVIDENCE FOR 2 DISTINCT SYNDROMES OF INVOLUTIONAL OSTEOPOROSIS [J].
RIGGS, BL ;
MELTON, LJ .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (06) :899-901
[38]  
Royal Australian College of General Practitioners (RACGP) and Osteoporosis Australia, 2020, OST PREV DIAGN MAN P
[39]  
Sanders K, 2010, Ann Intern Med, V153, pJC3, DOI 10.7326/0003-4819-153-6-201009210-02003
[40]   Hip protectors for preventing hip fractures in older people [J].
Santesso, Nancy ;
Carrasco-Labra, Alonso ;
Brignardello-Petersen, Romina .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (03)